- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- PhRMA report lists 271 vaccines in development
- ROUNDTABLE: Pharmacy’s future in sync with technology
- CDC: Flu activity remains elevated
SCHAUMBURG, Ill. — Generic drug maker Sagent Pharmaceuticals has launched a new drug for neuromuscular disorders, the company said.
Sagent announced the launch of vecuronium bromide, an injectable drug used to treat myasthenia gravis and Eaton-Lambert syndrome. The disorders cause muscle weakness and fatigue.
The market for vecuronium bromide is about $10 million in the United States, according to IMS Health.